Emerging retatrutide, a twin -action treatment targeting simultaneously GLP-1 and GIP receptors, is sparking considerable interest within the healthcare community. Early clinical trials have demonstrated significant reductions in physical weight and advancements in physiological markers for individuals with obesity . Scientists believe this ground-